LGND — Ligand Pharmaceuticals Incorporated Share News
0.000.00%
Last trade - 00:00- $5.95bn
- $5.72bn
- $215.02m
Brief: Ligand Hosts 2024 Investor And Analyst Day And Introduces 2025 Guidance
U.S. RESEARCH ROUNDUP-Citigroup, Salesforce, Zscaler
Ligand Pharmaceuticals Inc reports results for the quarter ended in September 30 - Earnings Summary
Brief: Ligand Reports Q3 2024 Financial Results And Raises 2024 Guidance
Brief: Ligand Pharmaceuticals Q3 EPS USD -0.39
Brief: Palvella Therapeutics Appoints Matthew Korenberg As Chief Financial Officer
Ligand Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Brief: Ligand Pharmaceuticals Q2 EPS USD -2.88
U.S. RESEARCH ROUNDUP- Hubspot, McDonald's, Tesla
Brief: Ligand Pharmaceuticals Inc Says Entered Amendment To Credit Agreement Dated Oct 12, 2023
Brief: Ligand To Acquire Apeiron Biologics AG For $100 Million
Brief: Lifecore Biomedical Announces Cooperation Agreement With 22NW
Brief: Ligand Partner Verona Pharma Announces FDA Approval Of Ohtuvayre For Maintenance Treatment Of COPD
Brief: Ligand Collaborator Merck Receives FDA Approval For Pneumococcal Vaccine For Adults
Brief: FDA Approved Merck's BLA For Pneumococcal 21-Valent Conjugate Vaccine Effective July 17
Brief: Ligand Pharmaceuticals Q1 EPS USD 4.75
Brief: Ligand And Agenus Enter Into $100 Million Royalty Financing Agreement
Ligand Pharmaceuticals Inc expected to post earnings of 78 cents a share - Earnings Preview
Brief: Ligand Pharmaceuticals Announces Launch Of Pelthos Therapeutics To Accelerate Commercialization Of Zelsuvmi